Scholar Rock Holding Corp (SRRK) company profile
Close on Nov 17, 2026Market cap $5.49BP/E –Yield –
About Scholar Rock
Biological Products, (No Diagnostic Substances), SIC 2836
Scholar Rock is a biopharmaceutical company focused on discovering and developing therapies for spinal muscular atrophy and other rare neuromuscular conditions. Using a proprietary platform that targets latent growth factor precursors within tissue microenvironments, the company builds an anti-myostatin pipeline. Its lead product candidates include apitegromab, an investigational monoclonal antibody designed to inhibit myostatin activation in muscle, and SRK-439. The company develops treatments intended for pediatric and adult patients suffering from debilitating neuromuscular disorders.
The company operates with clinical development activities spanning the United States and Europe, supported by a customer-facing workforce of approximately fifty professionals in the United States and commercial readiness initiatives beginning in Germany. It aims to serve patient populations across a platform covering more than fifty countries globally. The provided text mentions scientific roots at Harvard Medical School and Boston Children’s Hospital, but it does not state the city or location of the company's corporate headquarters.
Summary of the business section of Scholar Rock's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Scholar Rock Holding Corp
- Headquarters
- Cambridge, MA
- Address
- 301 Binney Street, 3rd Floor 02142
- Phone
- (857) 259-3860
- Website
- scholarrock.com
- Employees
- 289, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- SRRK
- Exchange
- Nasdaq
- IPO date
- May 24, 2018
- Shares outstanding
- 122M, Aug 3, 2026
- Public float
- $2.60B, Jun 30, 2025
- Filer category
- Non-accelerated filer
- SEC CIK
- 1727196
- CUSIP
- 80706P103
- ISIN
- US80706P1030
- FIGI
- BBG00KT2RRM6
- Share class FIGI
- BBG00KT2RSD4
- LEI
- 549300Z1FLPGL4OWJ459
- EIN
- 82-3750435
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David Hallal | Chief Executive Officer, Director | 1,844,034 |
| Akshay Vaishnaw | President of R&D, Director | 630,542 |
| Jay T. Backstrom | CHIEF EXECUTIVE OFFICER, Director | 425,561 |
| Keith Woods | Chief Operating Officer | 620,055 |
| Vikas Sinha | Chief Financial Officer | 619,856 |
| Mo Qatanani | CHIEF SCIENTIFIC OFFICER | 98,645 |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | 126,012 |
| Junlin Ho | GENERAL COUNSEL | 241,545 |
| Caryn Parlavecchio | CHRO | 169,087 |
| Tracey Sacco | Chief Commercial Officer | 76,250 |
| Erin Moore | Interim PFO and PAO | 96,173 |
| Edward H. Myles | COO & CFO | 111,345 |
| Srinivas Akkaraju | Director | 7,131,508 |
| Joshua Reed | Director | 20,466 |
| Katie Peng | Director | 34,322 |
| Michael Gilman | Director | 59,554 |
| Kristina Burow | Director | 2,460,368 |
| Jeffrey S. Flier | Director | 27,871 |
| Richard Brudnick | Director | 21,896 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 David Hallal | $33.30M | $44.34M | $13.56M | $487 | – |
| FY2025 Jay Backstrom | $17.49M | $6.15M | $13.56M | $487 | – |
| FY2024 | $7.99M | $35.21M | $3.02M | $478 | – |
| FY2023 | $4.11M | $10.54M | $2.16M | $208 | – |
| FY2022 Jay Backstrom | $7.08M | $7.18M | $2.78M | $36 | – |
| FY2022 Nagesh Mahanthappa | $2.84M | $371.63K | $2.78M | $36 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| David Hallal Chief Executive Officer and Chairman | $637.50K | $2.00M | $22.52M | $7.62M | $452.29K | $67.65K | $33.30M | – |
| Akshay Vaishnaw, M.D., Ph.D. President of R&D | $523.08K | $2.00M | $9.01M | $3.05M | $278.33K | $32.56K | $14.89M | – |
| R. Keith Woods Chief Operating Officer | $523.08K | – | $9.01M | $3.05M | $278.33K | $57.19K | $12.92M | – |
| Vikas Sinha Chief Financial Officer | $523.08K | – | $9.01M | $3.05M | $278.33K | $14.04K | $12.87M | – |
| Jay Backstrom, M.D., M.P.H. Former President and Chief Executive Officer | $600.23K | – | $5.90M | $9.85M | – | $1.15M | $17.49M | +119% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- May 24, 2018
- Offer price
- $14.00
- Securities offered
- 5,360,000
- Gross proceeds
- $75.04M
- Exchange
- Nasdaq
- First trading day
- May 24, 2018
- First-day close
- $15.50+10.7%
- Lock-up ends (est.)
- Nov 20, 2018
“The initial public offering price is $14.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of February 24, 2026, we had 289 full-time employees, of which 137 employees are engaged in research and development activities and 152 are engaged in general and administrative activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 3, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| May 12, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| May 24, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| May 21, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?